Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies

Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.

Small Flag of Malaysia Sticked in the Map Background with Selective Focus.

Pfizer Inc. and Gilead Sciences Inc. communications with the US Trade Representative show the companies' efforts to quash measures in Malaysia deemed harmful to the pharmaceutical industry, according to a series of communications obtained under the Freedom of Information Act by the nongovernmental organization Knowledge Ecology International (KEI).

KEI released the emails between the USTR and both companies in Nov. 28 and 29 blog postings. Pfizer's communications...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet